林信廷 Email and Phone Number

Work ExperienceGlaxoSmithKline Pharmaceuticals Limited Taiwan BranchSales Specialist 2023/02~ Present◆ Territory: Northern Taichung and Miaoli, including clinics and hospitals such as ChinaMedical University Hospital, Fongyuan Hospital and Da-Chien general Hospital. With responsibility acrossall medical departments. Focused on therapeutic areas such as cardiology, nephrology, metabolism…◆ Performance: Achieved a remarkable 154% of the Q4 2023 sales target, performance in 2023 reaches135.7%, with an outstanding 71.4% growth. Conducted over 29 events and effectively executed themarketing strategy, then listing our product in 42 new clients in 6 months.◆ Assisted supervisors in leading the team to improve seminar quality, enhance prevention awareness, andstrengthen the concept of self-pay through various programs.◆ Starting in 2024, served as the Diabetes Care Executive Lead for the team.AstraZeneca Taiwan LimitedSenior Medical Representatives 2018/04~2023/01◆ Territory: Hsinchu and Miaoli, including clinics and regional hospitals such as Chong Guang Hospital andHopedoc Hospital. Focused on therapeutic areas such as cardiology, nephrology, metabolism, and familymedicine.◆ Performance: 444.9% growth from 2018 to 2022, also achieve more than 100% every year, and award asBest Sales in 2021 and 2022◆ Collaborated with MacKay Memorial Hospital to engage Xiang'an Clinic for re-listing our product, andachieved more than 40 account listing◆ Actively participated in various internal projects. Including the Digitalization Task Force, Omnichannel TaskForce, Consensus Task Force, and Employee Resource Group.TAXO Pharmaceutical Co., LtdSenior Medical Representatives 2017/01~2018/03◆ Territory: Taichung and Changhua, including all clinics within the region.◆ Achieved the CP award in 2017, and was recognized as the Top Sales for pharmaceutical listing.Accomplished a 106% sales target achievement in 2017, with a remarkable 27% growth in sales.◆ Collaborated with the Changhua Clinic Association, we successfully listing over 20 account within one quarter after the meeting, achieving outstanding results in 2017.OtherPei Li Pharmaceutical Industrial Co., Ltd. 2012/11 2015/12SUCCESS Medical CO., LTD. 2012/01~2012/10SHINLIN SINSENG Pharmaceutical Co., Ltd. 2009/12~2011/12EducationChina Medical University, Taiwan.Master of De partment of Health Services Administration 2019/09~2021/06◆ Independent Research: Short term Effects of SGLT 2 Inhibitor drugs on complications in Patientswith Type 2 Diabetes.